Company intelligence
PhRMA
Research. Progress. Hope.
About PhRMA
We represent America’s innovative biopharmaceutical research & biotechnology companies, advocating for policies that support the discovery of new medicines and ensure broad patient access to safe, effective treatments. PhRMA is committed to working with stakeholders in Washington, across the country and around the world to: 🔹Expand patient access to safe and effective medicines through a free market, without price controls 🔹Protect strong intellectual property incentives 🔹Promote transparent, effective regulation and a free flow of information to patients We’re building a policy environment where science can thrive, patients can benefit and cures can exist.
Verified activity
Signals from PhRMA
6 published signals
Legal & Regulatory
PhRMA noted that in October 2025, the FDA approved a breakthrough treatment for pulmonary fibrosis, allowing patients in the United States to access it quickly.
Reported by PhRMA
Research & Knowledge
PhRMA published resources unpacking the facts behind claims about evergreening and product hopping in the America's IP system
Reported by PhRMA
Research & Knowledge
PhRMA published independent analyses projecting that more than $500 billion in planned manufacturing and infrastructure investment could be at risk, along with 1.5 million jobs nationwide under a broad MFN policy.
Reported by PhRMA